Oligo, an innovative new drug company based on RNA interference technology, announced on the 5th that it plans to participate in the 'JPM Healthcare Conference 2024 (JPM 2024 42nd Annual Healthcare Conference)' held in San Francisco, California, USA, from the 8th to the 11th of this month (local time) to seek global partnerships.
At this JPM conference, CEO Dong-ki Lee will personally attend business meetings with global pharmaceutical companies along with the business development team. A company representative stated, "Through this event, we plan to lay the foundation for joint research and technology transfer regarding our RNA interference therapeutic development platform technology and various therapeutic pipelines."
Oligo's clinical-stage pipeline includes ▲ OLX702A (OLX75016), a NASH and obesity treatment that received approval for Phase 1 clinical trial in Australia last month, ▲ OLX301A (OLX10212), a dry and wet age-related macular degeneration treatment currently in Phase 1 clinical trial in the United States, ▲ OLX101A (OLX10010), which is awaiting the final report of Phase 2 clinical trial results in the United States, and ▲ OLX104C (OLX72021), a hair loss treatment currently undergoing Phase 1 clinical trial in Australia.
CEO Dong-ki Lee said, "Regarding OLX702A, which is being developed as a treatment for NASH and obesity, we have signed non-disclosure agreements and are conducting in-depth discussions with multiple big pharma companies for follow-up meetings. Additionally, more detailed exchanges are expected in meetings with another big pharma company interested in the hair loss treatment OLX104C." He emphasized, "Although we attend the JPM event every year, this year we will do our best to make it a turning point for achieving large-scale technology transfer results that the market expects."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
